Article Versions Notes

Damerow H, Cheng X, von Kiedrowski V, Schirrmacher R, Wängler B, Fricker G, Wängler C. Toward Optimized ⁸⁹Zr-Immuno-PET: Side-by-Side Comparison of [⁸⁹Zr]Zr-DFO-, [⁸⁹Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [⁸⁹Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? Pharmaceutics. 2022; 14(10):2114. https://doi.org/10.3390/pharmaceutics14102114

Damerow, Helen, Xia Cheng, Valeska von Kiedrowski, Ralf Schirrmacher, Björn Wängler, Gert Fricker, and Carmen Wängler. 2022. "Toward Optimized ⁸⁹Zr-Immuno-PET: Side-by-Side Comparison of [⁸⁹Zr]Zr-DFO-, [⁸⁹Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [⁸⁹Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?" Pharmaceutics 14, no. 10: 2114. https://doi.org/10.3390/pharmaceutics14102114

Damerow, H., Cheng, X., von Kiedrowski, V., Schirrmacher, R., Wängler, B., Fricker, G., & Wängler, C. (2022). Toward Optimized ⁸⁹Zr-Immuno-PET: Side-by-Side Comparison of [⁸⁹Zr]Zr-DFO-, [⁸⁹Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [⁸⁹Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? Pharmaceutics, 14(10), 2114. https://doi.org/10.3390/pharmaceutics14102114